SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

GameStop Corp. engages in offering games and entertainment products through its ecommerce properties and stores. The firm’s stores and ecommerce sites operate primarily under the names GameStop, EB Games, and Micromania. It operates through the following geographical segments: United States, Canada, Australia, and Europe. The company was founded by Daniel A. DeMatteo in 1996 and is headquartered in Grapevine, TX.

Gamestop Corporation - Ordinary Shares - Class A

GameStop Corp

GameStop is trending as community members draw comparisons to other heavily shorted stocks like $BYND and $AMC, speculating about a potential short squeeze. The discussion is fueled by improving profitability and anticipation for Ryan Cohen's upcoming interview, though some express frustration with the stock's recent performance and caution against chasing meme stocks. Overall, the community is weighing the potential for a turnaround against concerns about short-term gains and the CEO's long-term vision.

RAGE GUY (RAGE) is a cryptocurrency inspired by the Rage Guy meme, one of the earliest and most recognizable characters from internet rage comics. The project captures the cultural legacy of early meme history and brings it onto the blockchain in tokenized form. It is designed as a community-driven digital asset that celebrates internet culture, nostalgia, and the role memes play in shaping online communities.

Rage Guy

RAGE CRYPTO is trending as community members rally around the OG meme coin, emphasizing its strong community and commitment to "working for their bags." Discussions highlight the importance of community, the staying power of memes versus coins, and the anticipation for a moonshot listing. The community aims to recapture the 2021 meme-centric market enthusiasm.

DraftKings, Inc. is a digital sports entertainment and gaming company, which engages in the provision of online sports betting, online casino, daily fantasy sports product offerings, DraftKings Marketplace, retail sportsbook, media, and other consumer product offerings. The company was founded by Jason D. Robins, Matthew Kalish, and Paul Liberman on December 31, 2011 and is headquartered in Boston, MA.

DraftKings Inc. - Ordinary Shares - Class A

DraftKings Inc

DKNG is trending as it moves into prediction markets with the acquisition of Railbird, aiming to expand beyond traditional sports betting; this has sparked discussions about the potential impact on existing sports betting regulations. Community chatter revolves around whether this move will unlock new markets and revenue streams, or if it's a defensive play against emerging competitors. Some are also debating if this will help regain previous highs and if there is a potential short squeeze.

Intuitive Surgical, Inc. engages in the provision of robotic-assisted surgical solutions and invasive care through a comprehensive ecosystem of products and services. Its products include Da Vinci Surgical and Ion Endoluminal systems. The company was founded by Frederic H. Moll, John Gordon Freund, and Robert G. Younge in November 1995 and is headquartered in Sunnyvale, CA.

Intuitive Surgical Inc

Intuitive Surgical is trending due to strong Q2 earnings and procedure growth, though margin concerns persist due to tariffs and costs. The community is weighing the impact of these factors, discussing potential price targets and whether the stock can maintain its upward momentum. Bullish sentiment is fueled by the company's dominance in surgical robotics and new product launches.

Welcome to SLAP – The Only Coin That Slaps Harder Than Your Moms  Tired of coins that claim they SLAP but are nothing but limp wrists? SLAP is here to SLAP some sense into the crypto space.  Founded by the Flutter of Five Fingers and powered by the Prancing of the Pried Palm, SLAP isn’t just another coin—it’s an attitude.  We’re not here to talk roadmaps, utility, or world peace. We’re here to SLAP charts, SLAP the haters, and SLAP our way to the top. No VC suits, no corporate nonsense—just raw, unfiltered internet culture with a side of “did we just do that?  ”So load your wallet, mute your financial advisor, and get ready to ride the most unhinged meme rocket. Open up your hands, and start swingin'. You never know what you could hit.  SLAP: It’s not a coin. It’s a lifestyle.

Slap

The Slap crypto community is buzzing about staking rewards and real-world partnerships, including sponsoring an MMA fighter. Amidst market fluctuations, discussions revolve around "buying the dips" and holding with conviction, especially with the project's recent listing on cryptotwits. The community emphasizes its correlation with the movements of ETH and BTC.

General Motors Co. engages in the designing, manufacturing, and selling of trucks, crossovers, cars, and automobile parts, and in providing software-enabled services and subscriptions. It operates through the following segments: GMNA, GMI, Cruise, and GM Financial. The company was founded by William C. Durant on September 16, 1908 and is headquartered in Detroit, MI.

General Motors Company

General Motors is trending following a strong Q3 earnings report that exceeded expectations and prompted an increased full-year outlook, driving investor optimism. The community is discussing the company's strategic operational changes and reduced tariff exposure, while some debate whether the recent surge is sustainable or a short-term spike. Broader discussions include GM's position relative to competitors in the EV market and the impact of government policies and tariffs.

Texas Instruments Incorporated engages in the design and manufacture of semiconductors. It operates through the following segments: Analog, Embedded Processing, and Other. The Analog segment semiconductors change real-world signals, such as sound, temperature, pressure or images, by conditioning them, amplifying them and often converting them to a stream of digital data that can be processed by other semiconductors, such as embedded processors. The Embedded Processing segment involves handling specific tasks and can be optimized for various combinations of performance, power, and cost, depending on the application. The company was founded in 1930 and is headquartered in Dallas, TX.

Texas Instruments Inc.

Texas Instruments is trending downwards after Q3 earnings and guidance sparked concerns among analysts regarding capex plans and end-market recovery, leading to community discussions around potential support levels and future performance. Despite a solid quarter, cautious guidance and tariff worries are weighing on sentiment, with some viewing the dip as a buying opportunity for long-term investors while others anticipate further declines.

Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates to treat central nervous system diseases. It develops Roluperidone for the treatment of negative symptoms in patients with schizophrenia and MIN-301 for the treatment of Parkinson’s disease. The company was founded by Rogerio Vivaldi Coelho and Goeffrey Robin Race on April 23, 2007 and is headquartered in Burlington, MA.

Minerva Neurosciences Inc

Minerva Neurosciences $NERV is trending due to a recent financing deal of up to $200 million to advance its schizophrenia treatment, roluperidone, through a Phase 3 trial. The community is actively discussing the potential for a significant price increase, with some anticipating a short squeeze, while others remain cautious due to past volatility and potential dilution. The focus remains on the drug's prospects and the impact of the funding on the company's future.

Sweetgreen, Inc. owns and operates a chain of salad restaurants. It offers drinks, sides, local bowls, salads, plates, and warm bowls. The company was founded by Nicolas Jammet, Jonathan Neman, and Nathaniel E. Ru in November 2006 and is headquartered in Los Angeles, CA.

Sweetgreen Inc - Ordinary Shares - Class A

Sweetgreen ($SG) is trending amid high short interest and anticipation of a potential squeeze, with traders closely watching volume and options activity.  The community is discussing the company's oversold condition and possible catalysts, including a potential gamma squeeze and upcoming earnings on November 6th. Some investors are optimistic, citing recent executive hires and a robotics play, while others express concerns about the company's valuation and profitability.

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflix is trending downwards after its earnings report, with discussions focusing on an EPS miss attributed to a Brazilian tax dispute. Community sentiment appears bearish, with some citing concerns about content and valuation, while others see a buying opportunity due to strong revenue growth and ad potential. The broader market impact and potential downgrades are also being closely watched.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>Shares surged 141% to $6.41, marking their highest level since February 2024, after Minerva secured up to $200 million in financing led by top healthcare investors.</li><li>The FDA cleared the design for a confirmatory Phase 3 trial of roluperidone, a potential treatment for the negative symptoms of schizophrenia.</li><li>Retail traders on Stocktwits turned “extremely bullish,” citing the new funding and FDA alignment as signs of confidence in an eventual approval.</li></ul>Minerva Neurosciences' stock jumped to a nearly two-year high on Tuesday after the biotech firm announced a new financing deal that could bring in up to $200 million and outlined a clear regulatory path with the U.S. FDA for its lead schizophrenia drug, roluperidone.The company’s shares&nbsp;soared 141% to $6.41 on Tuesday, hitting their highest level since February 2024, before slipping 6.4% in after-hours trading.<h2 class="st-heading-2">Funding For Phase 3 Trial And NDA Resubmission</h2>Minerva said it raised $80 million upfront through a private financing round backed by leading healthcare investors, including Vivo Capital, Janus Henderson Investors, and Federated Hermes Kaufmann Funds.&nbsp;The deal could bring in as much as $200 million in total, with another $80 million tied to the exercise of Tranche A warrants and an additional $40 million linked to future clinical milestones under Tranche B warrants. Each preferred share was priced at $1,000, convertible into common stock at $2.11 pending shareholder approval.The firm said the investment would fully fund its planned confirmatory Phase 3 study of roluperidone, and NDA resubmission to the FDA. It will also be used to make preparations for a potential U.S. commercial launch, should the product gain approval.<h2 class="st-heading-2">Strengthening The Team</h2>Under the agreement, Minerva will increase the number of its directors to include up to three new members with significant experience in schizophrenia and drug development. The company also plans to establish a Scientific Advisory Board to help guide the Phase 3 study.“We will now refocus all of our efforts on the successful execution of the confirmatory trial with the objective of demonstrating that roluperidone can effectively treat patients with impairing negative symptoms,” CEO Remy Luthringer said in a statement.<h2 class="st-heading-2">FDA Agrees On Clear Trial Design</h2>The FDA has agreed on the design of the confirmatory Phase 3 study, which will test roluperidone 64 mg as a standalone treatment in patients with schizophrenia who suffer from negative symptoms such as lack of motivation, social withdrawal, and diminished emotional expression. The main goal of the trial will be to measure improvements in the PANSS Marder Negative Symptoms Factor Score after 12 weeks.The FDA has also asked Minerva to observe patients for up to 52 weeks to monitor relapse rates, helping to build evidence for roluperidone as a monotherapy. The company expects around 25%–30% of trial participants to be enrolled from U.S. sites.<h2 class="st-heading-2">Stocktwits Traders Eye FDA Milestone Upside</h2>On Stocktwits, retail sentiment for Minerva was ‘extremely bullish’ amid a 102,300% surge in 24-hour message volume.One user said they expected Minerva’s stock to climb sharply if it breaks past the $7 level, while another pointed to the company’s $200 million financing as a sign of confidence, suggesting that such investment likely reflects optimism around eventual FDA approval.<stembedurl>https://stocktwits.com/24cmKarMadhfromPrishtina/message/633140308</stembedurl><stembedurl>https://stocktwits.com/Myway1000/message/633126607</stembedurl><a href="https://stocktwits.com/symbol/NERV">Minerva’s stock</a> has nearly tripled so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Minerva Neurosciences logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Minerva Neurosciences Stock Hits Near 2-Year High On FDA Pathway, $200M Boost — Retail Sees FDA Catalyst

Shares surged 141% to $6.41, marking their highest level since February 2024, after Minerva secured up to $200 million in financing led by top healthcare investors.

Equity

Minerva Neurosciences, Inc. (NASDAQ:NERV) Sees Significant Decline in Short Interest

Minerva Neurosciences, Inc. (NASDAQ:NERV  Get Free Report) was the recipient of a large decrease in short interest in March. As of March 15th, there was short interest totalling 38,300 shares...

Minerva Neurosciences Receives Complete Response Letter from FDA for New Drug Application for Roluperidone for the Treatment of Negative Symptoms in Patients with Schizophrenia

BURLINGTON, Mass., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central...

Minerva Neurosciences (NASDAQ:NERV) Cut to "Sell" at StockNews.com

StockNews.com downgraded shares of Minerva Neurosciences (NASDAQ:NERV  Free Report) from a hold rating to a sell rating in a research note published on Friday. Minerva Neurosciences Trading...

Minerva Neurosciences: Q4 Earnings Insights

Minerva Neurosciences Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Business Updates

BURLINGTON, Mass., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central...

Minerva Neurosciences (NASDAQ:NERV) Raised to Hold at StockNews.com

StockNews.com upgraded shares of Minerva Neurosciences (NASDAQ:NERV  Free Report) from a sell rating to a hold rating in a research note released on Monday. Minerva Neurosciences Stock...

Minerva Neurosciences (NASDAQ:NERV) Cut to Sell at StockNews.com

StockNews.com lowered shares of Minerva Neurosciences (NASDAQ:NERV  Free Report) from a hold rating to a sell rating in a research note issued to investors on Friday. Minerva Neurosciences...

Minerva Neurosciences (NASDAQ:NERV) Stock Rating Lowered by StockNews.com

Minerva Neurosciences (NASDAQ:NERV  Get Free Report) was downgraded by equities researchers at StockNews.com from a hold rating to a sell rating in a research...

Will Netflix ($NFLX) beat quarterly earnings? 
 
*Powered by Polymarket

Stocktwits

) beat quarterly earnings? 
 
*Powered by Polymarket

Fiscal Period	Estimated	Reported	Surprise	Result
Q2 '25	-$0.90	-$0.43	52.22%	BEAT
Q1 '25	-$1.07	-$0.50	53.27%	BEAT
Q4 '24	-$1.05	-$0.56	46.67%	BEAT
Q3 '24	-$1.01	$2.97	394.06%	BEAT
Q2 '24	-$0.97	-$1.09	-12.37%	MISSED

NERV
Minerva Neurosciences Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest Earnings Results: Q2 '25

Historical Earnings

Latest NERV News

NERVMinerva Neurosciences Inc